Haha I hear you about the flies. And I too have been tempted to keep mine safe in a drawer but then I’m afraid it will rot in there for want of ventilation and sunlight. That’s why I bit the bullet on this system that will dry it, disinfect it with UV light, AND keep it away from flies looking for nests. It wasn’t expensive on AliExpress but hope it’s not a piece of junk.
But what about her total care system? Did you try it or only tried the toothbrush? With something like that, I either go all in or I don’t, to give it a fair chance. So I ordered the toothbrushes and the birch sticks and the xylitol gum and mints and loose powder to boot — along with the 3rd party products and double checked they each were the variant she vouched for. If I don’t notice amazing teeth it won’t be for lack of faithful adherence.
Walking a Few Thousand Steps a Day May Reduce Alzheimer’s Risk
A new study suggests that exercise can be particularly beneficial for older people at a higher risk for the disease.
Walking a few thousand steps a day can slow cognitive decline in older adults who are at increased risk of developing Alzheimer’s disease, according to research published Monday. Getting about 3,000 to 5,000 daily steps was advantageous compared with doing less physical activity; the benefit peaked around 5,000 to 7,500 steps.
The link between exercise and dementia is well established, and many neurologists say physical activity is one of the best ways to reduce the odds of developing the condition. The new study, published in the journal Nature Medicine, sheds light on what might be playing out in the brain and who could benefit most from exercise.
“We’ve known for several decades that physical activity is associated with a reduced risk of developing dementia,” said Kirk Erickson, the chair of neuroscience at the AdventHealth Research Institute, who was not involved with the research. What the new study has done that is “really quite important and quite unique,” he said, is identify how exercise might be influencing some of the proteins implicated in Alzheimer’s disease.
Thank you! I’ve been waiting for this! I wish everything was moving faster😢. There are so many I’m waiting on. People are suffering, deteriorating and waiting unnecessarily long while these old systems are moving at the pace of 1900’s medicine. A horse drawn carriage in a rocket age.
Sorry to put a damper on this. Liraglutide and dementia
The ELAD clinical trial (NCT01843075) investigated liraglutide in 204 mild Alzheimer’s dementia patients over 12 months but failed its primary FDG-PET endpoint of preserving brain glucose metabolism. While researchers reported 50% reduced brain atrophy and slower cognitive decline on secondary measures, leading experts deemed the effect sizes too small for meaningful clinical significance. Despite initial positive media coverage, specialists classified it as a negative study overall. Two Phase 3 trials of semaglutide in dementia are expected to conclude in 2026.
We will have to await some further trials to see how much it affects cognitive decline. Though I don’t see how the reported reduction in brain atrophy does not translate into a reduction of cognitive decline.
Meanwhile, of course, it does have many other benefits.
Also, FWIW: ChatGPT-5 opinion:
There’s no strong reason to think liraglutide is uniquely capable of protecting the brain.
There is good reason to think this might be at least partly a GLP-1 “class effect.”
But we absolutely cannot assume that all GLP-1 / incretin drugs will give the same 50% reduction in brain atrophy until their own Alzheimer’s trials report.
Real-world data (JAMA Network Open 2025): GLP-1 RA users semaglutide + tirzepatide had a significantly lower risk of dementia vs users of other diabetes drugs +1
Findings In this cohort study of 60 860 patients, those treated with semaglutide or tirzepatide had significantly lower risks of dementia, stroke, and all-cause mortality compared with those receiving other antidiabetic drugs but no difference in the risk of Parkinson disease or intracerebral hemorrhage.
Meaning These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity.
